李氏大药厂(00950.HK):专有ADC项目ZK2401于中国提交新药临床试验申请获NMPA受理

智通财经
Jul 30
【李氏大药厂(00950.HK):专有ADC项目ZK2401于中国提交新药临床试验申请获NMPA受理】智通财经APP讯,李氏大药厂(00950.HK)发布公告,于2026年7月29日,本集团就ZK2401于中国的新药临床试验(IND)申请已获得中国国家药品监督管理局(NMPA)药品评审中心受理。ZK2401为李氏大药厂自主研发的专有抗体药物偶联物(ADC)项目,由李氏大药厂拥有该分子的完整全球知识产权。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10